TRDAEntrada Therapeutics
About Entrada Therapeutics
Entrada Therapeutics (NASDAQ:TRDA) is a biotechnology firm focused on the development of innovative therapies. The company specializes in creating drugs designed to engage intracellular targets, aiming to treat a broad range of diseases, including neuromuscular conditions and other serious ailments. Entrada Therapeutics is leveraging its proprietary platform to advance a portfolio of oligonucleotide and peptide therapeutics aimed at addressing unmet medical needs. With a commitment to science and patient care driving its operations, the firm is dedicated to pushing the boundaries of medicine to improve the lives of patients worldwide.
What is TRDA known for?
Snapshot
Public US
Ownership
2016
Year founded
169
Employees
Boston, United States
Head office
Loading Map...
Operations
All Locations
Boston, US
Produtos e/ou serviços de Entrada Therapeutics
- Developing an intracellular biologics delivery platform aimed at transforming the treatment of devastating diseases.
- Focusing on a Duchenne Muscular Dystrophy (DMD) program, leveraging their platform to address this genetic disorder.
- Advancing programs targeting Myotonic Dystrophy Type 1, utilizing novel therapeutics for this neuromuscular disease.
- Creating a broad pipeline of endosomal escape vehicle (EEV™)-fueled therapies for various diseases.
- Offering research and development services to create custom intracellular delivery solutions for biopharmaceutical companies.
- Exploring potential treatments for other rare diseases through their proprietary technology platform.
equipe executiva do Entrada Therapeutics
- Mr. Dipal DoshiCEO & Director
- Mr. Nathan J. DowdenPresident & COO
- Dr. Natarajan Sethuraman Ph.D.President of Research & Development
- Mr. Kory James Wentworth CPACFO & Treasurer
- Dr. Jared Cohen J.D., Ph.D.General Counsel
- Ms. Karla MacDonaldChief Corporate Affairs Officer
- Mr. Kevin Healy Ph.D.Senior Vice President of Regulatory Affairs
- Sandeep BasnetHead of Information Technology